Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1.
D000410:Alanine Transaminase / Q000097:blood; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D016572:Cyclosporine / Q000627:therapeutic use*; D051544:Cytochrome P-450 CYP3A; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism*; D004347:Drug Interactions; D006526:Hepatitis C / Q000601:surgery; D006801:Humans; D016031:Liver Transplantation / Q000276:immunology / Q000502:physiology* / Q000523:psychology; D008297:Male; D006899:Mixed Function Oxygenases / Q000378:metabolism*; D010879:Piperazines; D019966:Substance-Related Disorders / Q000150:complications / Q000188:drug therapy; D016559:Tacrolimus / Q000627:therapeutic use*; D014230:Triazoles / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use*
D018687:Antidepressive Agents, Second-Generation; D010879:Piperazines; D014230:Triazoles; C051752:nefazodone; D016572:Cyclosporine; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; C104464:CYP3A protein, human; D051544:Cytochrome P-450 CYP3A; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D016559:Tacrolimus